11,148 Shares in Gilead Sciences, Inc. $GILD Acquired by AGP Franklin LLC

AGP Franklin LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,148 shares of the biopharmaceutical company’s stock, valued at approximately $1,237,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Geode Capital Management LLC increased its position in Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares in the last quarter. Norges Bank bought a new position in shares of Gilead Sciences in the second quarter worth about $2,150,268,000. Invesco Ltd. lifted its position in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares in the last quarter. Finally, Amundi grew its stake in shares of Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after acquiring an additional 1,614,355 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple major banks raised price targets and kept bullish ratings, increasing investor conviction that upside remains (Citigroup to $156, UBS to $155, BMO to $150, Truist to $145). Analysts cited in these notes are maintaining buy/outperform views, which supports demand for GILD. Citigroup price‑target note UBS/Truist coverage BMO note
• Positive Sentiment: Press reports note GILD reached a new 1‑year high on the analyst upgrade momentum — a technical trigger that can attract momentum buyers and ETFs. AmericanBankingNews article
• Neutral Sentiment: Company fundamentals and guidance remain supportive: Gilead’s most recent quarter beat EPS and revenue expectations and management set FY2025 EPS guidance (8.05–8.25), which underpins analyst optimism but is not new today. (See analyst consensus and company metrics for context.) MarketBeat company summary
• Negative Sentiment: GILD’s CEO, Daniel Patrick O’Day, sold 115,640 shares (avg $135) in a disclosed transaction — a large insider sale that may prompt concern or profit‑taking among some investors despite his remaining sizeable stake. The SEC filing and trade detail are public. SEC Form 4 (insider sale) InsiderTrades report

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This represents a 16.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director directly owned 1,339 shares in the company, valued at $170,186.90. This trade represents a 67.69% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 247,397 shares of company stock worth $31,986,612. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $140.97 on Wednesday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm’s 50-day moving average is $124.53 and its 200 day moving average is $119.10. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $141.71. The company has a market capitalization of $174.90 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 0.72 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Analysts Set New Price Targets

GILD has been the subject of a number of recent analyst reports. Needham & Company LLC upped their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. UBS Group lifted their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday. Wells Fargo & Company increased their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. BMO Capital Markets upped their price objective on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, HSBC lifted their target price on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $135.36.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.